Andhra officials keep check on 38 essential Covid drugs deccanchronicle.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from deccanchronicle.com Daily Mail and Mail on Sunday newspapers.
According to the EoI document, applications should be submitted before June 17 through email. "The EoI submitted by industries will be scrutinised by a Technical Assessment Committee (TAC). Only up to 15 industries will be given ToT on their capabilities, technical hand holding capability of DRDO and on First Come First Served Basis," it said.
Requirements for the bidders include a drug license to manufacture Active Pharmaceutical Ingredient (API) from Drug Licensing Authorities and WHO GMP (Good Manufacturing Practices) certification
Lee Pharma informed they would file application for getting approval from drug regulator.(FILE)
New Delhi:
Hyderabad-based Lee Pharma has entered into an agreement with the Indian Institute of Chemical Technology (IICT), a constituent laboratory of CSIR, to manufacture and commercialise 2-Deoxy-D-Glucose (2-DG) used to treat Covid patients, a statement said on Wednesday.
An integrated pharmaceutical company, Lee Pharma entered into the non-exclusive licensing agreement for the synthesis of 2-DG, recently developed by DRDO and Dr Reddy's Laboratories.
The drug has received approval for use in COVID-19 patients. It has been found to help speed up recovery and reduce oxygen dependence, and Dr. Reddy''s Laboratories has launched the drug in the form of sachets.
Guidelines for Using Anti-COVID Drug 2-DG are Out Now by Saisruthi Sankaranarayanan on June 3, 2021 at 7:07 PM "Directions for use of 2-DG in COVID-19 patients as per DCGI approval"
This "Made-in-India" drug 2-Deoxy-D-Glucose was developed by DRDO. Previously, the first batch of this drug was released on
17 May by Defence Minister Rajnath Singh and Health Minister Harsh Vardhan.
Key takeaways from the guidelines
‘2-DG must be prescribed to patients who developed moderate to severe forms of SARS-CoV-2 infections and caution must be exercised while using it on people with comorbidities.’
The drug 2-DG must only be prescribed to COVID patients who have been hospitalized by moderate to severe forms of the infection.
COVID-19 drug 2-DG not for everyone, DRDO issues directions for usage
COVID-19 drug 2-DG not for everyone, DRDO issues directions for usage
The drug could be a game-changer in the battle against the pandemic as it helps in faster recovery of hospitalised patients.
Share
Updated: Jun 1, 2021, 11:48 PM IST
The Defence Research and Development Organisation (DRDO) on Tuesday issued directions on the usage of the new COVID-19 drug 2-DG.
The DRDO said that patients with uncontrolled diabetes, severe cardiac problem, acute respiratory distress syndrome (ARDS), severe hepatic and renal impairment should be cautious before taking this medicine. The drug can be given to patients under the care and prescription of doctors, DRDO said.